( convenience for patientscommented Dr...)Genta Announces Results of Phase 1 Study Using Genasense,Administered by Intermittent Subcutaneous Injection,Health

convenience for patients," commented Dr. Raymond P. Warrell, Jr., Chairman and CEO of Genta. "We are continuing dose escalation in the brief IV schedule and hope to incorporate these regimens into future studies using new agents that are administered on daily or weekly schedules."

Preclinical studies have demonstrated that high-dose intermittent treatment with Genasense was associated with increased uptake of the drug within tumors and yielded superior efficacy when combined with paclitaxel, temozolomide, (Temodar(R); Schering Plough, Inc.) and multiple kinase inhibitors (erlotinib, imatinib, sunitinib, and sorafenib) in a highly aggressive model of malignant melanoma. A summary of these preclinical data can be viewed at: http://www.genta.com/Genta/InvestorRelation/2006/press_20061109.html

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its oligonucleotide program. The leading drug in Genta's small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. Genta is partnered with IDIS (www.idispharma.com) on a program whereby both Ganite(R) and Genasense(R) are available on a "named- patient" basis in countries outside the United States. For more information about Genta, please visit our website at: www.genta.com.<
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference